Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GB263T in advanced NSCLC and other solid tumors
CTR20221422Phase 2Active
- Sponsor
- Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology
- Start
- Jul 2022
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of GB263T in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (3 arms), sponsored by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology. Primary endpoints: Adverse events and serious adverse events, Dose-limiting toxicity and 1 more. Started Jul 2022; status: active.
02
Drugs
GB263T
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20221422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221422.